Aumolertinib as a first-line treatment for <em>EGFR</em>-mutated non-small cell lung cancer: a real-world study

Aumolertinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a real-world study

GUO Mingyuan, DUAN Xiaoman, WANG Haitao, ZHU Jun, ZHANG Yu, ZHAO Yanbin

PDF(3277 KB)

Tumor website：www.tumorsci.org E-mail Alert

PDF(3277 KB)

Tumor ›› 2025, Vol. 45 ›› Issue (01) : 35-46. DOI: 10.3781/j.issn.1000-7431.2025.2403-0169

Original Research

Aumolertinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a real-world study

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 45(01): 35-46 https://doi.org/10.3781/j.issn.1000-7431.2025.2403-0169

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}

{{article.copyrightLicense_en}}

PDF(3277 KB)

Accesses

Citation

Detail

Sections

Recommended

/

〈

〉